Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
Alpha Tau Medical announced positive overall survival and favorable safety results from a pooled analysis of three Phase I/II clinical studies of its Alpha DaRT therapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. The treatment demonstrated median overall survival times notably exceeding historical data in secon…